Biogen to fund mapping of ALS genome (Boston Business Journal)
Biogen Idec (NASDAQ: BIIB) has entered into a research collaboration with Duke University and the HudsonAlpha Institute for Biotechnology designed to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The goal is to gain a better understanding of the genetic causes of ALS, in order to come up with better potential treatments.
|Navigenics' Vance Vanier.|
Johnson & Johnson firm seeking new use for Simponi (Philadelphia Business Journal)
Janssen Biotech and Janssen Biologics are requesting Food and Drug Administration and European Medicines Agency approval to make their Simponi drug a treatment for "adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy."
A watershed moment in the fight against HIV (Boston Business Journal)
|Human Genome Sciences CEO Tom Watkins|
MedImmune will open new center, shift 40 jobs to Hayward (San Francisco Business Times)
Moody's downgrades Thermo Fisher on Lamba acquisition (Boston Business Journal)